Zobrazeno 1 - 10
of 228
pro vyhledávání: '"Nobuyuki, Mizunuma"'
Autor:
Hitomi Kamo, Eiji Shinozaki, Takanobu Sugase, Nobuyuki Mizunuma, Shoji Taniguchi, Takashi Gotoh, Keisyo Chin, Tomoaki Tanaka, Kazumi Koga, Kensei Yamaguchi
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-6 (2019)
Abstract Background Panitumumab is the first human combinatorial antibody for the treatment of metastatic colorectal carcinoma. Dermatologic toxicity of all grades occurs in more than 90% of patients. However, there are few reports of purpura induced
Externí odkaz:
https://doaj.org/article/7364b43388fa4c8ba52451b3c5bc1b54
Autor:
Eiji Shinozaki, Kazuhiro Tanabe, Takashi Akiyoshi, Tomohiro Tsuchida, Yuko Miyazaki, Nozomi Kojima, Masahiro Igarashi, Masashi Ueno, Mitsukuni Suenaga, Nobuyuki Mizunuma, Kensei Yamaguchi, Konosuke Nakayama, Sadayo Iijima, Toshiharu Yamaguchi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background Carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19–9 are used in clinical practice as tumor markers to diagnose or monitor colorectal cancer (CRC) patients, However, their specificities and sensitivities are not idea
Externí odkaz:
https://doaj.org/article/b437e9d9679d4d29974b6b411d1610a4
Autor:
Heinz-Josef Lenz, Nobuyuki Mizunuma, Wataru Ichikawa, Martin D. Berger, Satoshi Okazaki, Anish Parekh, Yan Ning, Dongyun Yang, Masashi Ueno, Ana Sebio, Yu Sunakawa, Diana L. Hanna, Shu Cao, Wu Zhang, Satoshi Matsusaka
Supplementary Table 1. Summary of EMT-related SNPs Supplementary Table 2A. Association between baseline characteristics and clinical outcomes in the bevacizumab cohort Supplementary Table 2B. Association between baseline characteristics and clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98164c18f1a9c8669cb7f002a725f587
https://doi.org/10.1158/1535-7163.22503264
https://doi.org/10.1158/1535-7163.22503264
Autor:
Kiyoshi Hasegawa, Akio Saiura, Tadatoshi Takayama, Shinichi Miyagawa, Junji Yamamoto, Masayoshi Ijichi, Masanori Teruya, Fuyo Yoshimi, Seiji Kawasaki, Hiroto Koyama, Masaru Oba, Michiro Takahashi, Nobuyuki Mizunuma, Yutaka Matsuyama, Toshiaki Watanabe, Masatoshi Makuuchi, Norihiro Kokudo
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0162400 (2016)
The high recurrence rate after surgery for colorectal cancer liver metastasis (CLM) remains a crucial problem. The aim of this trial was to evaluate the efficacy of adjuvant therapy with uracil-tegafur and leucovorin (UFT/LV).In the multicenter, open
Externí odkaz:
https://doaj.org/article/233bab300e96429cbe2dce9fe1ea758d
Autor:
Soichiro Ishihara, Satoshi Matsusaka, Hideomi Yamashita, Keisaku Kondo, Kazushige Kawai, Masashi Fujii, Masashi Ueno, Yojiro Hashiguchi, Toshifusa Nakajima, T. Shimbo, Yuichi Ishikawa, Masahiko Oguchi, Nobuyuki Mizunuma, Eiji Sunami, Daiki Kato, Keisuke Uehara, Keiko Murafushi, Masanori Nakazawa, Hisanaga Horie, Tohru Okada, Junji Okuda
Publikováno v:
Radiotherapy and Oncology. 134:199-203
Purpose The study was designed to evaluate the safety and efficacy of adding oxaliplatin to py (CRT) with S-1 in patients with locally advanced rectal carcinoma (LARC). We report here the final results of the study. Patients and methods Patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0de78e63eb03560ef9a60db1285b127
https://doi.org/10.1016/j.radonc.2019.02.006
https://doi.org/10.1016/j.radonc.2019.02.006
Autor:
Nobuyuki Mizunuma, Junji Yamamoto, Shinichi Miyagawa, Masanori Teruya, Tadatoshi Takayama, Michiro Takahashi, Masayoshi Ijichi, Kiyoshi Hasegawa, Masatoshi Makuuchi, Fuyo Yoshimi, Masaru Oba, Seiji Kawasaki, Yutaka Matsuyama, Akio Saiura, Hiroto Koyama, Takashi Kokudo, Norihiro Kokudo, Soichiro Ishihara
Publikováno v:
Surgery. 170(4)
Background Although liver resection is the only potentially curative treatment for colorectal liver metastases, recurrence is frequent. We previously published the early results of a randomized controlled phase 3 trial showing that adjuvant therapy w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef740ad8f6abe2c105fddee845d18fbc
https://pubmed.ncbi.nlm.nih.gov/34030885
https://pubmed.ncbi.nlm.nih.gov/34030885
Autor:
Kensei Yamaguchi, Nozomi Kojima, Masashi Ueno, Kazuhiro Tanabe, Mitsukuni Suenaga, Yuko Miyazaki, Tomohiro Tsuchida, Nobuyuki Mizunuma, Takashi Akiyoshi, Eiji Shinozaki, Konosuke Nakayama, Masahiro Igarashi, Sadayo Iijima, Toshiharu Yamaguchi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Cancer
BMC Cancer
Background Carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19–9 are used in clinical practice as tumor markers to diagnose or monitor colorectal cancer (CRC) patients, However, their specificities and sensitivities are not ideal, and no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a76604e8cea505bb45792e8776f99b0
http://link.springer.com/article/10.1186/s12885-018-4252-6
http://link.springer.com/article/10.1186/s12885-018-4252-6
Autor:
Eiji Shinozaki, Nobuyuki Mizunuma, Tomoaki Tanaka, Shoji Taniguchi, K. Chin, Kazumi Koga, Takanobu Sugase, Hitomi Kamo, Kensei Yamaguchi, Takashi Gotoh
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-6 (2019)
Journal of Medical Case Reports
Journal of Medical Case Reports
Background Panitumumab is the first human combinatorial antibody for the treatment of metastatic colorectal carcinoma. Dermatologic toxicity of all grades occurs in more than 90% of patients. However, there are few reports of purpura induced by anti-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf059b06cf4cf51eaa16ef542ddc17f
https://doi.org/10.1186/s13256-018-1877-7
https://doi.org/10.1186/s13256-018-1877-7
Autor:
Go Miyata, Tatsuo Kagimura, Kenichi Sugihara, Nobuyuki Mizunuma, Masamichi Yasuno, Takamichi Komori, Akio Shiomi, Megumi Ishiguro, Hiroyuki Uetake
Publikováno v:
International journal of clinical oncology. 24(5)
The TRICC0808 trial is a phase II multi-institutional trial that investigated the efficacy of preoperative mFOLFOX6 + bevacizumab (BV) therapy for liver-only metastasis that is unsuitable for upfront resection. The R0 resection rate in the efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21dec9e529879adb6d9db634b608f5b8
https://pubmed.ncbi.nlm.nih.gov/30612267
https://pubmed.ncbi.nlm.nih.gov/30612267
Autor:
Dongyun Yang, Satoshi Okazaki, Heinz-Josef Lenz, Nobuyuki Mizunuma, Wu Zhang, Yan Ning, Satoshi Matsusaka, Martin D. Berger, Masashi Ueno, Ana Sebio, Wataru Ichikawa, Anish Parekh, Shu Cao, Diana L. Hanna, Yu Sunakawa
Publikováno v:
Molecular Cancer Therapeutics. 15:1405-1411
The epithelial–mesenchymal transition (EMT) is an important mechanism of resistance to angiogenesis inhibition. The ability of EMT pathway genetic variants to predict the efficacy of antiangiogenic therapy is unknown. We analyzed associations betwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34543d923ed7de25f5ac4ecbe455013d
https://doi.org/10.1158/1535-7163.mct-15-0751
https://doi.org/10.1158/1535-7163.mct-15-0751